Double-blinded, Vehicle Controlled Study to Evaluate Efficacy & Tolerance of Bakuchiol and Ethyl Linoleate on Acne

Acne Vulgaris Clinical Trial

Official title:

A Randomized, Double-blinded, Vehicle Controlled, Monocentric Study to Evaluate the Efficacy and Tolerance of Synergistic Combination of Bakuchiol and Ethyl Linoleate on Mild to Moderate Acne Vulgaris

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05069272
• Other study ID #: SYTPIG1M
• Status: Recruiting
• Phase: N/A
• Start date: September 10, 2021
• Est. completion date: January 30, 2025

Study information

• Verified date: October 2021
• Source: Sytheon Ltd.
• Contact: Jack Donnelly
• Phone: 44(0)1617911797
• Email: jack[@]princetonconsumer.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Subjects will be assigned to a active cream or vehicle to compare the cosmetic effects. This will take place over a 12 week period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 30, 2025
• Est. primary completion date: February 20, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy female volunteers, aged 18 years or older;
• with mild to moderate acne;
• Subjects must have between 10-100 non-inflammatory lesions and 10-50 inflammatory lesions but no more than 2 nodular lesions and no cysts on their face.
• If applicable, users of estrogens/birth control pills must have been on the treatment regimen for at least 3 months and be willing to continue use for study duration; Females of child-bearing potential (FCBP): A female is considered not to be of childbearing potential if she is post-menopausal with at least 12 consecutive months of amenorrhea or has undergone surgical sterilization. While on the study, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described

below:

• Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR
• Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• Willing to follow study instructions and available to attend the study visits;
• Willing to provide written informed consent and sign photography release

Exclusion Criteria:

• Female subjects: Self-reported pregnant or breast feeding, or planning to become pregnant during the course of the study;
• Known allergy or hypersensitivity to acne treatment products;
• Current skin disease of any type in the test area (e.g. eczema, psoriasis, rosacea, seborrheic dermatitis, vitiligo, etc.), or under the treatment of a doctor for any skin condition;
• Have any cystic acne, acne conglobate, acne fulminans, or secondary acne (chloracne or drug-induced acne) in the test area;
• Any conditions on the test site that would interfere with evaluations (i.e. tattoos, scars, open cuts, sunburn, piercings, excessive hair, etc.);
• Use of topical treatments such as OTC (over the counter) acne medication topical anti-inflammatory medications, salicylic acid, corticosteroids, antibiotics, anti-bacterials, peroxide-containing products, or retinoids within 2 weeks of baseline;
• Use of depigmenting medications such as hydroquinone during the 14 days prior to the study start; Insulin dependent diabetes;
• Concurrent medication that might affect the response to the test articles including routine use of anti-inflammatory medications, anti-histamines, and steroids;
• History of Crohn's disease, or clinically significant enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis);
• Microdermabrasion or laser treatment in the test area within six months of the study;
• Medical condition which, in the opinion of the Investigator, would compromise the safety of the subject or confound study results;
• Use of systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4 weeks of baseline;
• Use of other anti-acne medications, including isotretinoin or spironolactone, within 6 months of baseline;
• Participation on an investigational drug study within 4 months of the baseline visit.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Other:
• Bakuchiol and Ethyl Linoleate
A synergistic combination of Bakuchiol and Ethyl Linoleate
• Vehicle
No actives

Locations

Country	Name	City	State
United Kingdom	Princeton Consumer Research Corp	Chelmsford	England

Sponsors (1)

Lead Sponsor	Collaborator
Ratan K. Chaudhuri

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IGA Score	IGA score of zero (clear) or one (almost clear)	From baseline to week 12
Primary	Facial lesions	Percent reductions in facial lesion counts for inflammatory and noninflammatory	From baseline to week 12
Secondary	Total lesion count	Percent change in Global Face Total Lesion Count	From baseline to week 2
Secondary	Total lesion count	Percent change in Global Face Total Lesion Count	From baseline to week 4
Secondary	Total lesion count	Percent change in Global Face Total Lesion Count	From baseline to week 8
Secondary	Total lesion count	Percent change in Global Face Total Lesion Count	From baseline to week 12
Secondary	IGA score	IGA score of zero (clear) or one (almost clear) as compared to vehicle	From baseline to week 2, 4, 8, 12
Secondary	IGA score	IGA score of zero (clear) or one (almost clear)	From baseline to week 4
Secondary	IGA score	IGA score of zero (clear) or one (almost clear)	From baseline to week 8
Secondary	IGA score	IGA score of zero (clear) or one (almost clear)	From baseline to week 12
Secondary	IGA score	IGA score of zero (clear) or one (almost clear) as compared to vehicle	From baseline to week 2, 4, 8 & 12
Secondary	Inflammatory and non-inflammatory leisons	Percent reductions in facial lesion counts for inflammatory and noninflammatory	From baseline to week 2
Secondary	Inflammatory and non-inflammatory leisons	Percent reductions in facial lesion counts for inflammatory and noninflammatory	From baseline to week 4
Secondary	Inflammatory and non-inflammatory leisons	Percent reductions in facial lesion counts for inflammatory and noninflammatory	From baseline to week 8
Secondary	Inflammatory and non-inflammatory leisons	Percent reductions in facial lesion counts for inflammatory and noninflammatory	From baseline to week 12
Secondary	Inflammatory and non-inflammatory leisons	Percent reductions in facial lesion counts for inflammatory and noninflammatory as compared to vehicle	From baseline to week 2, 4, 8 & 12
Secondary	Post inflammatory hyperpigmentation	Percent reduction in overall post inflammatory hyperpigmentation	From baseline to week 2
Secondary	Post inflammatory hyperpigmentation	Percent reduction in overall post inflammatory hyperpigmentation	From baseline to week 4
Secondary	Post inflammatory hyperpigmentation	Percent reduction in overall post inflammatory hyperpigmentation	From baseline to week 8
Secondary	Post inflammatory hyperpigmentation	Percent reduction in overall post inflammatory hyperpigmentation	From baseline to week 12
Secondary	Post inflammatory hyperpigmentation	Percent reduction in overall post inflammatory hyperpigmentation as compared to vehicle	From baseline to week 2, 4, 8 & 12